250 related articles for article (PubMed ID: 28324049)
1. Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial.
McInnes N; Smith A; Otto R; Vandermey J; Punthakee Z; Sherifali D; Balasubramanian K; Hall S; Gerstein HC
J Clin Endocrinol Metab; 2017 May; 102(5):1596-1605. PubMed ID: 28324049
[TBL] [Abstract][Full Text] [Related]
2. Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin.
McInnes N; Hall S; Sultan F; Aronson R; Hramiak I; Harris S; Sigal RJ; Woo V; Liu YY; Gerstein HC
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32403130
[TBL] [Abstract][Full Text] [Related]
3. Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial.
McInnes N; Hall S; Lochnan HA; Harris SB; Punthakee Z; Sigal RJ; Hramiak I; Azharuddin M; Liutkus JF; Yale JF; Sultan F; Smith A; Otto RE; Sherifali D; Liu YY; Gerstein HC;
Diabetes Obes Metab; 2023 Nov; 25(11):3347-3355. PubMed ID: 37580972
[TBL] [Abstract][Full Text] [Related]
4. Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial.
McInnes N; Hall S; Hramiak I; Sigal RJ; Goldenberg R; Gupta N; Rabasa-Lhoret R; Braga M; Woo V; Sultan F; Otto R; Smith A; Sherifali D; Liu YY; Gerstein HC;
Diabetes Care; 2022 Jan; 45(1):178-185. PubMed ID: 34728531
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
Rosenstock J; Diamant M; Aroda VR; Silvestre L; Souhami E; Zhou T; Perfetti R; Fonseca V;
Diabetes Care; 2016 Sep; 39(9):1579-86. PubMed ID: 27284114
[TBL] [Abstract][Full Text] [Related]
6. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
7. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.
Yang W; Liu J; Shan Z; Tian H; Zhou Z; Ji Q; Weng J; Jia W; Lu J; Liu J; Xu Y; Yang Z; Chen W
Lancet Diabetes Endocrinol; 2014 Jan; 2(1):46-55. PubMed ID: 24622668
[TBL] [Abstract][Full Text] [Related]
8. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
9. Association of an intensive lifestyle intervention with remission of type 2 diabetes.
Gregg EW; Chen H; Wagenknecht LE; Clark JM; Delahanty LM; Bantle J; Pownall HJ; Johnson KC; Safford MM; Kitabchi AE; Pi-Sunyer FX; Wing RR; Bertoni AG;
JAMA; 2012 Dec; 308(23):2489-96. PubMed ID: 23288372
[TBL] [Abstract][Full Text] [Related]
10. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
[TBL] [Abstract][Full Text] [Related]
11. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
12. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
13. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
Han J; Yu H; Tu Y; Pang J; Liu F; Bao Y; Yang W; Jia W
Diabet Med; 2017 Apr; 34(4):490-499. PubMed ID: 27151271
[TBL] [Abstract][Full Text] [Related]
14. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
15. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
16. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Bunck MC; Diamant M; Cornér A; Eliasson B; Malloy JL; Shaginian RM; Deng W; Kendall DM; Taskinen MR; Smith U; Yki-Järvinen H; Heine RJ
Diabetes Care; 2009 May; 32(5):762-8. PubMed ID: 19196887
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a basal insulin + 2-3 oral antihyperglycaemic drugs regimen versus a twice-daily premixed insulin + metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open-label, randomized controlled BEYOND-V trial.
Pan Q; Li Y; Wan H; Wang J; Xu B; Wang G; Jiang C; Liang L; Feng W; Liu J; Wang T; Zhang X; Cui N; Mu Y; Guo L;
Diabetes Obes Metab; 2022 Oct; 24(10):1957-1966. PubMed ID: 35642463
[TBL] [Abstract][Full Text] [Related]
19. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
